Table 5.6d

Immunosuppression Use for Maintenance by Regimen

Prior to Discharge, 1996 to 2005

Recipients with Kidney Transplants

  Transplant Year
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Functioning Graft at Discharge 10,889 11,241 11,999 12,274 13,103 13,812 14,323 14,689 15,535 16,005
With Immunosuppression Info 10,687 11,195 11,931 12,089 12,886 13,788 14,260 14,614 15,402 15,523
--- + MMF/MPA 0.0% 0.1% 0.3% 0.1% 0.1% 0.1% 0.2% 0.4% 0.4% 0.5%
--- + MMF/MPA + Other Antimet 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
--- + MMF/MPA + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.1% 0.2% 0.2% 0.4% 0.6% 0.3%
--- + MMF/MPA + Steroids 2.0% 2.4% 2.6% 2.8% 1.6% 1.4% 1.2% 1.6% 1.7% 2.0%
--- + Other Antimet 0.1% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
--- + Other Antimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
--- + Other Antimet + Steroids 3.6% 0.5% 0.3% 0.3% 0.1% 0.1% 0.1% 0.0% 0.0% 0.0%
--- + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.1% 0.3% 0.1% 0.2% 0.4% 0.2%
--- + Siro/Evero + Steroids 0.0% 0.0% 0.1% 0.2% 0.5% 0.5% 0.4% 0.6% 0.4% 0.2%
--- + Steroids 5.3% 1.5% 2.1% 1.9% 1.2% 1.0% 0.8% 1.3% 1.7% 1.4%
CyA 0.3% 0.4% 0.3% 0.2% 0.1% 0.1% 0.1% 0.2% 0.2% 0.1%
CyA + MMF/MPA 0.6% 0.5% 0.7% 0.6% 0.9% 0.9% 0.7% 1.6% 1.7% 1.3%
CyA + MMF/MPA + Other Antimet 0.1% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
CyA + MMF/MPA + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.1% 0.2% 0.2% 0.2% 0.0% 0.0%
CyA + MMF/MPA + Steroids 39.2% 50.0% 48.2% 46.7% 37.1% 27.6% 22.9% 18.3% 14.2% 10.0%
CyA + Other Antimet 0.4% 0.3% 0.2% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
CyA + Other Antimet + Siro/Evero 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
CyA + Other Antimet + Steroids 23.1% 14.5% 8.8% 5.7% 3.6% 2.2% 0.8% 0.4% 0.2% 0.1%
CyA + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.1% 0.1% 0.4% 0.9% 1.2% 1.3%
CyA + Siro/Evero + Steroids 0.7% 1.5% 2.9% 1.9% 5.0% 3.6% 2.9% 2.2% 1.4% 1.2%
CyA + Steroids 8.6% 6.3% 5.4% 5.0% 3.1% 1.7% 1.2% 1.4% 1.4% 0.4%
Tac 0.1% 0.1% 0.1% 0.2% 0.5% 1.1% 2.0% 1.0% 1.3% 1.4%
Tac + MMF/MPA 0.1% 0.3% 0.6% 0.8% 1.1% 1.7% 2.9% 6.6% 13.7% 19.2%
Tac + MMF/MPA + Other Antimet 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.0%
Tac + MMF/MPA + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.1% 0.2% 0.4% 1.2% 0.7% 0.5%
Tac + MMF/MPA + Steroids 6.0% 12.5% 20.2% 26.4% 31.4% 38.6% 46.1% 46.8% 46.4% 50.6%
Tac + Other Antimet 0.0% 0.0% 0.1% 0.0% 0.1% 0.1% 0.0% 0.1% 0.1% 0.1%
Tac + Other Antimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Tac + Other Antimet + Steroids 2.1% 1.9% 1.9% 1.4% 1.1% 1.3% 1.1% 0.9% 0.5% 0.2%
Tac + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.4% 1.2% 1.3% 1.7% 1.9% 1.1%
Tac + Siro/Evero + Steroids 0.0% 0.0% 0.0% 0.2% 4.4% 6.4% 4.8% 4.7% 3.4% 2.4%
Tac + Steroids 3.3% 2.9% 2.9% 3.2% 3.5% 3.9% 3.3% 2.2% 2.5% 2.3%
Other Regimen 4.2% 4.1% 2.3% 2.2% 3.7% 5.5% 6.0% 4.9% 3.8% 3.0%


Source: OPTN/SRTR Data as of May 1, 2006.

Percentages in each column sum to 100 percent.

---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; Other Antimet: Antimetabolites excluding MMF and MPA.

"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.